Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $1.8 million.

  • Intellia Therapeutics' Gains from Sales and Divestitures rose 3502.2% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 3502.2%. This contributed to the annual value of $1.4 million for FY2024, which is 11175.07% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Gains from Sales and Divestitures of $1.8 million as of Q3 2025, which was up 3502.2% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Gains from Sales and Divestitures ranged from a high of $1.8 million in Q3 2025 and a low of $26235.0 during Q2 2021
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $545744.0 (2023), whereas its average is $704911.2.
  • In the last 5 years, Intellia Therapeutics' Gains from Sales and Divestitures skyrocketed by 2335.46% in 2022 and then soared by 55068.65% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $119715.0 in 2021, then grew by 23.35% to $147674.0 in 2022, then surged by 358.48% to $677055.0 in 2023, then soared by 111.75% to $1.4 million in 2024, then rose by 25.76% to $1.8 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.8 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.5 million for Q1 2025.